
Zealand Pharma's first phase III trial with dasiglucagon for the treatment of congenital hyperinsulinism did not reach its primary endpoint, according to a statement issued by the firm. The company is, however, pleased with some of the partial results in the study and looks forward to developing drugs for the disease going forward.
The firm currently awaits results coming from a different phase III trial involving the rare disease, which entails low blood sugar levels caused by abnormally high insulin levels in the blood. In this trial, dasiglucagon is tested on infants with congenital hyperinsulinism.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app